Generex Augments Antigen Express Scientific Advisory Board
WORCESTER, Mass. and TORONTO, May 18, 2012 /PRNewswire/ — Generex Biotechnology Corporation (OTCBB: GNBT) announced today that additional members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company’s AE37 breast cancer vaccine. The following distinguished scientists, scholars, and physicians join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School of Medicine Melvin and Bren Simon Cancer Center), Dr. Hope S. Rugo, MD (University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center), Dr. Keith L. Knutson, PhD (Mayo Clinic), and Dr. James J. Mule, MD (Moffitt Cancer Centre) on the SAB, the inaugural meeting of which is scheduled for May 19, 2012 in Dallas, TX:
Dr. Ian Krop, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Dr. Krop received his MD and PhD degrees from the Johns Hopkins School of Medicine in 1996 and completed a residency in internal medicine at Johns Hopkins Hospital. After completing a medical oncology fellowship at the Dana-Farber Cancer Institute, he joined the faculty of the Women’s Cancer Program at Dana-Farber and Harvard Medical School where he is now an Assistant Professor of Medicine and Director of Clinical Research for the Breast Oncology Center. His clinical and laboratory research focuses on developing novel molecularly targeted therapies for breast cancer treatment and on understanding and overcoming mechanisms of resistance to HER2-directed therapies. He has been a leader in the development of the antibody-drug conjugate trastuzumab-DM1 (T-DM1). He has led several biopsy intensive preoperative clinical trials of trastuzumab and bevacizumab based therapies with the goal of identifying resistance mechanisms and biomarkers of activity of these agents. His lab has also developed an optimized approach to collecting and molecularly characterizing circulating tumor cells and is using this method as an alternative strategy for identifying resistance mechanisms in the metastatic setting. He is co-chair of the HER2 working group of the Translational Breast Cancer Research Consortium and a member of the Susan G. Komen for the Cure Scientific Advisory Council.
Upon his appointment to the SAB, Dr. Krop commented: “The goal of my participation on the Antigen Express Scientific Advisory Board is to assist the company in optimizing a Phase III clinical development plan for AE37, a novel therapeutic approach to HER2 expressing breast cancer.”
Dr. Nuhad Ibrahim, MD
MD Anderson Cancer Center
Dr. Nuhad K Ibrahim is a Professor in the Department of Breast Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. He is an active clinical and translational investigator of breast cancer who has led multiple Phase III trials including randomized, multi-institutional studies. He has published extensively, including original manuscripts of vaccine trials in metastatic breast cancer. Dr. Ibrahim is a member of the Breast Cancer Clinical Research committee and organizes monthly seminars in clinical and translational immunology of breast cancer at MD Anderson Cancer Center. In addition, Dr. Ibrahim focuses his research efforts to develop clinical calculators that help predict risk of breast cancer recurrence to brain, bone, and other organs, and he is much involved in evaluating several agents in the management of metastasis of breast cancer to the brain.
Dr. Ibrahim received a dual undergraduate degree in Biology and Chemistry from American University of Beirut, Lebanon, and his MD in Medicine at the Baghdad Medical College, Baghdad, Iraq. He completed surgical residencies and his Fellowship in Clinical Hematology-Oncology at the American University of Beirut Medical Center, Beirut, Lebanon. Upon his emigration to the United States, Dr, Ibrahim completed residencies in Internal Medicine at SUNY Health Science Center, Brooklyn, NY and at St. Luke’s-Roosevelt Hospital, New York, NY, and a Postdoctoral Fellowship in Medical Oncology at The University of Texas MD Anderson Cancer Center.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation